Mar. 10 at 11:49 AM
$VALN stock moving up....
Primary efficacy data from the VALOR Phase 3 trial for Valneva's VLA15 Lyme disease vaccine candidate (in partnership with Pfizer) are expected in the first half of 2026. This follows the observation period through the end of the 2025 Lyme season, with full top-line results anticipated after that window closes.No exact release date has been announced yet. Valneva and Pfizer typically provide short notice via press releases or ad-hoc announcements when data readout is imminent.If results are positive, regulatory submissions to the FDA and EMA could follow later in 2026. The program already holds Fast Track designation in the US, which could expedite review.
